Related references
Note: Only part of the references are listed.A signature of immune function genes associated with recurrence-free survival in breast cancer patients
Maria Libera Ascierto et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Elizabeth A. Mittendorf et al.
CANCER (2012)
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
Anupama Sharma et al.
CANCER (2012)
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Mahsa Mohebtash et al.
CLINICAL CANCER RESEARCH (2011)
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2011)
Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
David G. DeNardo et al.
CANCER DISCOVERY (2011)
The role of the microenvironment in tumor immune surveillance
Oluwadayo Oluwadara et al.
BIOINFORMATION (2011)
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors
Sujin Lee et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
New Insights of CTLA-4 into Its Biological Function in Breast Cancer
H. Mao et al.
CURRENT CANCER DRUG TARGETS (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
J. Rafael Sierra et al.
MOLECULAR CANCER (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
Christina Yau et al.
BREAST CANCER RESEARCH (2010)
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
M. Zahidunnabi Dewan et al.
CLINICAL CANCER RESEARCH (2009)
Behavior of immune players in the tumor microenvironment
Mikael J. Pittet
CURRENT OPINION IN ONCOLOGY (2009)
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
Leisha A. Emens et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cancer Associated Fibroblasts Promote Tumor Growth and Metastasis by Modulating the Tumor Immune Microenvironment in a 4T1 Murine Breast Cancer Model
Debbie Liao et al.
PLOS ONE (2009)
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Achim Rody et al.
BREAST CANCER RESEARCH (2009)
FOXP3+ Tregs and B7-HI+/PD-I+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients:: Implication for immunotherapy
Hazem Ghebeh et al.
BMC CANCER (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells
Satoko Matsumura et al.
JOURNAL OF IMMUNOLOGY (2008)
Immune escape as a fundamental trait of cancer: focus on IDO
G. C. Prendergast
ONCOGENE (2008)
Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review
Teresa Petrella et al.
CANCER TREATMENT REVIEWS (2007)
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
Mark Barok et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Modification of the tumor microenvironment to enhance immunity
Yu-Pei Liao et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2007)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
SJ Antonia et al.
CLINICAL CANCER RESEARCH (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
N Tsavaris et al.
BRITISH JOURNAL OF CANCER (2002)
Share Paper
